Daiichi Sankyo & AstraZeneca v. Seagen: Federal Circuit Reverses, Invalidates Enhertu ADC Patent
Daiichi Sankyo and AstraZeneca asserted US10808039B2 — a patent covering antibody-drug conjugate technology underlying the blockbuster cancer therapy Enhertu — against Seagen. After a district court jury found infringement, the Federal Circuit reversed on appeal, holding the patent invalid for failing written description and enablement requirements. The reversal eliminates a damages award and willful infringement finding after 798 days of proceedings.
Federal Circuit invalidates key Enhertu ADC patent on written description and enablement
Daiichi Sankyo, together with AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd., filed this appeal (Case No. 23-2424) at the Court of Appeals for the Federal Circuit on 26 September 2023, seeking review of a district court verdict against Seagen, Inc. The asserted patent — US10808039B2 (application no. US16/507839) — covers antibody-drug conjugate technology central to Enhertu, a HER2-directed ADC that has become one of oncology’s highest-profile therapeutics. Seagen, an ADC-specialist acquired by Pfizer, was the defendant in the underlying infringement action.
The Federal Circuit closed the case on 2 December 2025, reversing the district court’s denial of Seagen’s motion for judgment as a matter of law. The appellate panel held that the ‘039 patent fails to satisfy both the written description and enablement requirements of 35 U.S.C. § 112, rendering it invalid. As a direct consequence, the court vacated the jury’s willful infringement finding and the associated damages award — eliminating what had been a plaintiff-side trial victory at the district level.
The 798-day timeline from filing to Federal Circuit decision reflects a typical appellate schedule for complex biotech patent disputes. The reversal on § 112 grounds — rather than on claim construction, obviousness, or infringement — is analytically significant: written description and enablement challenges are fact-intensive and not easily reversed on appeal, making this outcome a notable win for Seagen and its acquirer Pfizer. The public record does not disclose the original damages quantum or settlement negotiations, leaving the broader commercial impact partially uncertain.
Filing to Case Reversed in 798 days
798-day appeal lifecycle, roughly 2.2 years from filing to Federal Circuit decision
Federal Circuit reverses: what the invalidation means for both parties
Reversal on § 112: the appellate standard applied
A Federal Circuit reversal means the appellate panel found reversible legal error in the district court’s ruling — here, the denial of Seagen’s motion for JMOL on validity. The court held that no reasonable jury could find the ‘039 patent satisfied § 112’s written description and enablement requirements. This is a high bar: appellate courts typically defer to jury findings, making outright reversal on § 112 grounds a relatively uncommon and consequential outcome.
Patent invalidated — § 112 failureDaiichi Sankyo & AstraZeneca lose patent protection for Enhertu ADC claims
The reversal extinguishes the enforceability of the ‘039 patent. Daiichi Sankyo and AstraZeneca lose a tool that had secured a jury verdict — including a willful infringement finding — at the district level. While Enhertu’s commercial position may rest on additional IP and regulatory exclusivities, the ‘039 patent can no longer be used to exclude competitors or generate licensing revenue in its current form. Further appeal to the Supreme Court remains theoretically available but faces long odds.
Patent unenforceableSeagen and Pfizer: damages liability eliminated, ADC freedom restored
Seagen — now part of Pfizer’s oncology portfolio — emerges with its ADC operations shielded from the damages award and willful infringement finding that had survived trial. Invalidation on § 112 grounds provides a clean exit: no royalty obligations, no enhanced damages exposure, and no injunction risk tied to this patent. For Pfizer, which completed the Seagen acquisition during the proceedings, the outcome removes a significant financial liability from its ADC pipeline.
Liability eliminatedADC sector: § 112 risk becomes a primary battleground for broad biotech claims
This outcome signals that broadly drafted ADC patents — particularly those claiming wide classes of conjugate structures or linker-payload combinations — face heightened vulnerability under written description and enablement scrutiny. Companies developing next-generation ADC platforms should audit their patent portfolios for § 112 exposure. The ruling may also encourage defendants in pending ADC infringement actions to sharpen JMOL motions targeting specification support, given the Federal Circuit’s willingness to reverse on this basis.
Sector-wide § 112 risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Daiichi Sankyo | Individual | Biopharmaceutical companies — co-holders and licensees of US10808039B2 covering Enhertu ADCSearch in Eureka ↗ |
| Co-Plaintiff | Astrazeneca Pharmaceuticals, LP | Company | Search in Eureka ↗ |
| Co-Plaintiff | AstraZeneca UK, Ltd. | Company | Search in Eureka ↗ |
| Defendant | Seagen, Inc. | Company | Seagen, Inc. — antibody-drug conjugate specialist, acquired by Pfizer during proceedingsSearch in Eureka ↗ |
| Plaintiff counsel | Bradley Keith Ervin | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Plaintiff counsel | Christopher Neil Sipes | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas Lane Evoy | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Plaintiff counsel | Robert Jason Fowler | Attorney | Counsel for Daiichi SankyoSearch in Eureka ↗ |
| Plaintiff law firm | Covington & Burling, LLP | Law Firm | Representing Daiichi SankyoSearch in Eureka ↗ |
| Defendant counsel | Brian Robert Matsui | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Bryan J. Wilson | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Dane Sowers | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Devon Wesley Edwards | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew A. Chivvis | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew Ian Kreeger | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Sara Tonnies Horton | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant counsel | Seth W. Lloyd | Attorney | Counsel for Seagen, Inc.Search in Eureka ↗ |
| Defendant law firm | Morrison & Foerster LLP | Law Firm | Representing Seagen, Inc.Search in Eureka ↗ |
| Defendant law firm | Willkie Farr & Gallagher LLP | Law Firm | Representing Seagen, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s ruling is unambiguous: the panel reversed on JMOL, declared the ‘039 patent invalid for failing § 112’s written description and enablement requirements, and vacated both the willful infringement finding and the jury’s damages award. The phrasing ‘we reverse the district court’s denial of judgment as a matter of law’ signals the panel found no legally sufficient evidentiary basis for the jury’s validity conclusion. Vacating — rather than reversing — the willful infringement and damages findings is technically distinct: those issues are nullified as moot consequences of invalidity, not independently adjudicated on their merits.
US10808039B2 — Antibody-Drug Conjugate Technology Underlying Enhertu
US10808039B2, filed under application number US16/507839, protects antibody-drug conjugate technology that forms a core element of Enhertu (trastuzumab deruxtecan, DS-8201), a HER2-directed ADC co-developed by Daiichi Sankyo and AstraZeneca. ADC patents in this class typically cover conjugation chemistry, linker design, payload selection, and antibody specificity — a multi-component technical domain where the breadth of claims relative to specific examples in the specification is a recurring vulnerability under § 112.
Enhertu has achieved blockbuster status in HER2-positive breast, gastric, and lung cancers, making its underlying patent estate one of the most commercially significant in oncology. The invalidation of the ‘039 patent on written description and enablement grounds — rather than on prior art — suggests Daiichi Sankyo claimed a broader ADC structural scope than the specification demonstrably supported. For competitors and biosimilar developers, this creates a potential freedom-to-operate wedge, though the full Enhertu patent portfolio likely contains additional patents covering specific formulations, dosing methods, or manufacturing processes.
Should you run an FTO analysis against US10808039B2 and the Enhertu ADC portfolio?
Any company developing HER2-directed antibody-drug conjugates, ADC linker-payload platforms, or competing oncology biologics in the trastuzumab-conjugate space should treat this case as a prompt for structured FTO review. While US10808039B2 is now invalid, Daiichi Sankyo and AstraZeneca hold a broader Enhertu patent family — including formulation, manufacturing, and method-of-treatment claims — that remains potentially active and enforceable. The reversal narrows but does not eliminate IP risk for ADC developers targeting overlapping HER2 indications.
PatSnap Eureka’s FTO Search Agent can systematically map the surviving Enhertu patent family, flag claims still in force across key jurisdictions, and identify specification-scope gaps that could support invalidity arguments. For R&D teams designing next-generation ADC candidates with HER2-targeting or similar linker-payload architectures, Eureka can generate a claim-by-claim freedom-to-operate landscape — surfacing both blocking patents and prior art that may support challenge strategies informed by this Federal Circuit decision.
Run a freedom-to-operate analysis on US10808039B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ADC and biopharmaceutical § 112 patent cases
Explore Federal Circuit cases involving antibody-drug conjugate patents, § 112 written description and enablement invalidity, and oncology biologic IP disputes comparable to Case No. 23-2424.
What this case signals for the ADC and biopharmaceutical IP landscape
The Federal Circuit’s invalidation of a core Enhertu patent reshapes how ADC innovators should draft, prosecute, and enforce their most valuable claims.
Broad ADC patent claims require airtight specification support to survive appeal
The Federal Circuit’s willingness to reverse a jury verdict on § 112 grounds underscores that even commercially successful, jury-vindicated patents are vulnerable if the specification fails to adequately describe and enable the full scope of claimed subject matter. ADC patent holders should audit existing grants for written description breadth mismatches before asserting them in litigation.
Pfizer-Seagen gains strategic clarity: ADC pipeline free of this patent’s reach
With the ‘039 patent invalidated, Pfizer’s integration of Seagen’s ADC platform proceeds without the overhang of a willful infringement damages award. This outcome demonstrates that well-resourced defendants willing to press § 112 invalidity through JMOL motions can reverse unfavorable jury verdicts — a tactical lesson for other ADC defendants in pending actions.
Sankyo v Seagen — key questions answered
The Federal Circuit reversed the district court’s denial of Seagen’s motion for judgment as a matter of law, holding that US10808039B2 — a patent covering Enhertu ADC technology — is invalid for failing § 112’s written description and enablement requirements. The court also vacated the jury’s willful infringement finding and damages award.
The Federal Circuit found that the ‘039 patent failed to satisfy 35 U.S.C. § 112’s written description and enablement requirements. This means the patent’s specification did not adequately describe the full scope of the claimed antibody-drug conjugate technology, nor sufficiently enable a person skilled in the art to make and use the full claimed scope without undue experimentation.
The invalidation of US10808039B2 removes one layer of patent protection from Enhertu, but Daiichi Sankyo and AstraZeneca likely hold additional patents covering the drug’s formulation, dosing methods, manufacturing, and specific conjugation chemistry. The public record of this case does not confirm the full scope of the surviving Enhertu IP estate, so market exclusivity implications require a broader portfolio analysis.
§ 112 reversals on written description and enablement are relatively uncommon at the Federal Circuit because appellate courts typically defer to jury fact-finding. A reversal signals the panel found the inadequacy so clear that no reasonable jury could conclude otherwise. For patent holders, this outcome underscores the risk of asserting broadly claimed biotech patents where the specification’s specific examples may not support the full structural scope claimed.
Both were vacated by the Federal Circuit as a direct consequence of the patent invalidity ruling. A vacatur — as distinct from a reversal — nullifies these findings without adjudicating their independent merits: because the underlying patent is invalid, there can be no infringement and therefore no basis for damages or an enhanced willful infringement award.
PatSnap Eureka searches patents and litigation data to answer instantly.